Boston Scientific Co. (NYSE:BSX) Stock Position Trimmed by EPG Wealth Management LLC

EPG Wealth Management LLC decreased its position in Boston Scientific Co. (NYSE:BSX) by 4.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 15,650 shares of the medical equipment provider’s stock after selling 649 shares during the period. EPG Wealth Management LLC’s holdings in Boston Scientific were worth $1,398,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the company. TFC Financial Management Inc. increased its position in Boston Scientific by 308.8% in the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 210 shares during the period. Colonial Trust Co SC grew its stake in shares of Boston Scientific by 1,625.0% in the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 260 shares in the last quarter. West Oak Capital LLC acquired a new position in shares of Boston Scientific during the fourth quarter valued at $29,000. Valley National Advisers Inc. raised its stake in shares of Boston Scientific by 262.4% during the fourth quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 286 shares in the last quarter. Finally, Fairway Wealth LLC bought a new stake in shares of Boston Scientific during the fourth quarter valued at about $36,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Vance R. Brown sold 4,826 shares of the stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $95.09, for a total value of $458,904.34. Following the transaction, the senior vice president now owns 36,193 shares in the company, valued at approximately $3,441,592.37. This represents a 11.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Michael F. Mahoney sold 164,443 shares of Boston Scientific stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $102.48, for a total transaction of $16,852,118.64. Following the completion of the sale, the chief executive officer now owns 1,535,706 shares of the company’s stock, valued at $157,379,150.88. This trade represents a 9.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 307,025 shares of company stock valued at $31,742,060 in the last three months. Insiders own 0.50% of the company’s stock.

Boston Scientific Trading Down 0.0 %

NYSE:BSX opened at $104.22 on Wednesday. The stock’s 50-day moving average is $98.71 and its two-hundred day moving average is $95.66. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. The stock has a market cap of $154.15 billion, a PE ratio of 83.38, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68. Boston Scientific Co. has a fifty-two week low of $71.88 and a fifty-two week high of $107.17.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The firm had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. During the same quarter in the prior year, the business earned $0.56 EPS. The company’s revenue for the quarter was up 20.9% compared to the same quarter last year. As a group, equities research analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on BSX. StockNews.com raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, April 29th. Barclays raised their price objective on shares of Boston Scientific from $118.00 to $125.00 and gave the company an “overweight” rating in a research note on Friday, April 25th. Argus set a $130.00 target price on Boston Scientific in a research report on Tuesday, February 18th. Wells Fargo & Company lifted their price target on Boston Scientific from $100.00 to $118.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Finally, Evercore ISI upped their price objective on Boston Scientific from $110.00 to $112.00 and gave the company an “outperform” rating in a report on Thursday, April 24th. Twenty-three equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Buy” and a consensus target price of $114.52.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.